This study aimed to evaluate the efficacy of molecular-targeted therapies in patients with PsA presenting with enthesitis in comparison with placebo or TNF-α inhibitors (TNFis), especially adalimumab, and identify the latest evidence on their efficacy for PsA-related enthesitis. This evidence concerns the gene TNF and enthesitis.